Table 3 Estimates and enriched categories of differentially ^a regulated non-common genes

Pooled

Up-regulated [50]

WNT signaling

[NRCAM, WNT16]

(0)

DNA damage-induced responses and apoptosis

[CHEK1]

(<0.01)

Role of 14-3-3 proteins in cell cycle regulation

[CHEK1]

(<0.02)

Cadherins mediated cell adhesion

[CHP]

(<0.03)

Endothelial cell contacts by non-junctional mechanisms

[CHP]

(<0.03)

Role of SCF complex in cell cycle regulation

[CHEK1]

(<0.03)

ATM/ATR regulation of cell cycle

[CHEK1]

(<0.04)

nNOS signaling in neuronal synapses

[RASD1]

(<0.03)

Activation of astroglial cell proliferation by ACM3

[ERBB3]

(<0.04)

G-protein signaling in RhoA regulation pathway

[ARHGAP26]

(<0.04)

CDK5 in apoptosis and survival

[ERBB3]

(<0.04)

ERBB-family signaling

[ERBB3]

(<0.05)

Regulation of ElF2 activity associated with translation

[CSNK1G1]

(<0.05)

Ligand-independent activation of ESR1 and ESR2

[ERBB3]

(<0.05)

Non-genomic action of androgen receptor

[WNT16]

(<0.05)

Down-regulated [41]

Regulation of glucose and lipid metabolism

[APOE]

(0)

GDNF signaling

[ITGB1]

(<0.04)

Immune response involving antigen presentation by MHC class I

[HLA-C]

(0.05)

Chemotaxis involving CCR4-induced leukocyte adhesion

[ITGB1]

(<0.05)

Stage 3

Up-regulated [4]

No specific enriched category identified

Down-regulated [48]

Cytoskeleton remodeling involving RalB and RalA regulation pathway

[RALGDS]

(<0.01)

Clathrin coated vesicle formation

[MYO1D]

(<0.02)

Transcriptional silencing involving HP1 family

[PFDN5]

(<0.02)

G-protein signaling involving interaction among Ras-family GTPases and K-RAS/N-RAS/H_RAS regulation pathway

[RALGDS]

(<0.03)

Stage 4

Up-regulated [31]

Cell contraction involving relaxin and GPCRs

[ADCY6, EDNRA, RXFP1]

(0)

Development involving endothelin-1/EDNRA signaling

[ADCY6, EDNRA]

(0)

DNA damage induced apoptosis and DNA repair

[NBN]

(<0.01)

Beta-2 adrenergic dependent CFTR expression

[ADCY6]

(<0.01)

Regulation of lipid metabolism

[PPARA]

(<0.02)

Alpha-1 adrenergic receptor signaling

[ADCY6]

(<0.02)

Mu- and kappa-type opioid receptor mediated physiological process

[ADCY6]

(<0.03)

Mucin expression via IL-6, IL-17 signaling pathways

[TRAF3IP2]

(<0.04)

G-protein signaling

[ADCY6]

(<0.04)

Down-regulated [3]

Transport from Golgi and ER to the apical membrane

[PPIA]

(0)

Intracellular cholesterol and sphingolipids transport

[PPIA]

(<0.01)

Proliferative phase

Up-regulated [109]

RAS regulation pathway

[BCR, RASGRF1]

(0)

TC21 regulation pathway

[BCR, RASGRF1]

(0)

Regulation of CDC42 activity

[BCR, FGFR1]

(<0.01)

Sin3 and NuRD mediated transcription regulation

[CHD3, SIN3A]

(<0.01)

GDNF family signaling

[GFRA2, NRTN]

(<0.01)

Phospholipid metabolism

[GPD2, NRTN]

(<0.02)

Immune response involving CD40 signaling

[IRF1, TRAF3IP2]

(<0.02)

Down-regulated [20]

Cytoskeleton remodeling involving α-1A adrenergic receptor

Dependent inhibition of PI3K and regulation of actin by Rho GTPases

[LAMB1, MYL12B]

(<0.01)

Cell contraction involving δ-type opioid receptor, S1P2 receptor, ACM

[MYL12B]

(<0.01)

Development associated MAG dependent inhibition of neurite outgrowth

[MYL12B]

(<0.01)

Development associated with TGF-beta dependent induction of EMT via RhoA, PI3K and ILK

[TPM1]

(<0.01)

Cell adhesion involving histamine H1 receptor

[MYL12B]

(<0.01)

Cell adhesion and chemotaxis involving integrin

[LAMB1, MYL12B]

(<0.01)

Chemotaxis involving inhibitory action of lipoxins on IL-8 and leukotriene B4-induced neutrophil migration

[MYL12B]

(<0.01)

GPCRs in platelet aggregation

[MYL12B]

(<0.02)

Immune response involving CCR3 signaling in eosinophils

[MYL12B]

(<0.02)

Oxidative phosphorylation

[UQCR11]

(<0.03)

Secretory phase

Up-regulated [17]

Transport involving RAN regulation pathway

[TNPO1]

(<0.01)

Immune response involving MIF-JAB1 signaling

[PGR]

(<0.01)

nNOS signaling in neuronal synapses and circadian rhythm

[RASD1]

(<0.02)

Cell cycle associated spindle assembly and chromosome separation

[TNPO1]

(<0.02)

Regulation of lipid metabolism

[TNPO1]

(<0.02)

Regulation of glycogen metabolism

[AGL]

(<0.02)

Progesterone mediated maturation

[PGR]

(<0.02)

Cell adhesion associated ECM remodeling

[MME]

(<0.03)

TGF-beta receptor signaling in development

[TNPO1]

(<0.03)

Down-regulated [122]

Cell contraction involving δ-type opioid receptor

[MYL9]

(0)

Development associated Slit-Robo signaling

[DPYSL2, ROBO3]

(<0)

Insulin mediated regulation of translation

[ElF4EBP1, PPP1CC]

(<0.01)

Leukotriene 4 biosynthesis and metabolism

[GGT5, LTA4H]

(<0.01)

Chemotaxis involving inhibitory action of lipoxins on IL-8 and leukotriene B4-induced neutrophil migration

[MYL9, RAC2)

(<0.01)

Endoplasmic reticulum stress response pathway

[ATF4, PPP1CC]

(<0.01)

Immune response involving CCR3 signaling in eosinophils

[MYL9, RAC2]

(<0.03)

GTP-XTP metabolism

[GUK1, NME3, POLR3H]

(<0.03)

Cytoskeleton remodeling via RalB regulation pathway

[RALGDS]

(<0.04)

Eutopic

Up-regulated [182]

Cytoskeleton remodeling involving ACM3 and ACM4

[CHRM4, GNAQ]

(0)

G-protein signaling involving regulation of cAMP levels by ACM

[CHRM4, GNAQ]

(0)

Transcription involving Tubby signaling and HP1 family

[GNAQ]

(0)

Regulation of lipid metabolism involving G-alpha(q) regulation

[GNAQ, PTGS2]

(0)

Cell contacts by non-junctional mechanisms

[ITGA5, MAG1, PECAM1]

(<0.01)

NMDA –dependent neurophysiological process

[GNAQ, GRIN2A]

(<0.01)

Cell cycle at metaphase check point

[CBX3, INCENP]

(<0.01)

G-protein signaling involving Rap1A regulation pathways

[MAGI1, RAPGEF1]

(<0.02)

Regulation of translation through EIF4F activity

[EIF4A2]

(<0.03)

Regulation of translation by alpha-1 adrenergic receptors

[EIF4A2, GNAQ]

(<0.03)

Development involving endothelin-1/EDNRA signaling

[GNAQ, NPPB]

(<0.03)

Cytoskeleton remodeling via FAK signalin

[GNAQ, RAPGEF1]

(<0.04)

Immune response involving PGE2 common pathways

[GNAQ, PTGS2]

(<0.03)

Immune response involving IL-17 signaling pathways

[CXCL3, PTGS2]

(<0.04)

Cell contraction via oxytocin signaling

[GNAQ, PTGS2]

(<0.04)

Transcription via PPAR pathway

[MED1, PTGS2]

(<0.04)

Regulation of lipid metabolism through alpha-1 adrenergic receptors signaling via arachidonic acid

[GNAQ, PTGS2]

(<0.05)

Down-regulated [48]

Cell cycle regulation involving SCF complex

[CDC34, NEDD8, UBA52]

(0)

p53 regulation involving SUMO

[UBA52]

(<0.02)

Regulation of degradation and traffic of CFTR

[DYNLL1, UBA52]

(<0.02)

WNT signaling pathway involving degradation of bete-catenin

[UBA52]

(<0.03)

Transcriptional silencing involving HP1 family

[PFDN5]

(<0.03)

Immune response involving IL-12 and MIF-JAB1 signaling pathways

[UBA52]

(<0.03)

Angiotensin signaling via beta-arrestin

[CLTA, UBA52]

(<0.03)

ATM/ATR regulation of G1/S and G2/M checkpoints

[UBA52]

(<0.04)

NGF signaling for apoptosis and survival

[EPB41L1]

and activation of NF-kB

[UBA52]

(<0.04)

Neurophysiological process involving GABA-A receptor life cycle

[CLTA]

(<0.04)

Regulation of translation initiation

[EIF1, RPL7, RPL12, RPL15, RPL21, RPL22, RPL29, RPS3A, RPS10, RPS14, UBA52]

(<0.04)

Transition and termination of DNA replication

[UBA52]

(<0.04)

Activin A signaling regulation

[UBA52]

(<0.05)

Ectopic

Up-regulated [665]

Beta-2 adrenergic-dependent CFTR expression

[ADCY2, ADRB3, CREB1, PRKAR1B, PRKAR2B]

(0)

Mu-type opioid receptor mediated neurophysiological process

[ADCY2, ADCY5, CREB1, HPCA, PRKAR1B, PRKAR2B]

(0)

Development involving alpha-1 and beta-adrenergic receptors signaling via cAMP and PIP3 signaling

[ADCY2, ADCY5, AKT3, CREB1, FOXO3, GAB1, PRKAR1B, PRKAR2B, YWHAE]

(0)

Cell adhesion involving ephrin signaling

[ADAM10, EFNA5, EPHA4, EPHB6]

(0)

Transport involving RAB3 regulation pathway

[DMXL2, RAB3B]

(0)

Neurophysiological process involving corticoliberin signaling via CRHR1

[ADCY2, ADCY5, CACNA1C, CREB1, PRKAR2B, IVL]

(0)

Signal transduction involving cAMP and PKA signaling

[ADCY2, ADCY5, CACNA1C, CREB1, PRKAR1B, PRKAR2B, PCTK1]

(0)

G-protein signaling involving G-Protein beta/gamma signaling cascades

[ADCY2, ADCY5, AKT3, PRKAR1B, PRKAR2B]

(0)

G-protein signaling involving RhoA regulation pathway

[ARHGEF2, EFNA5, EPHA4, MCF2L]

(0)

eNOS activity in cell contraction

[ADCY5, CACNA1C, PRKAR1B,PRKAR2B, PRKG1]

(0)

MAG-dependent inhibition of neurite outgrowth

[NGFR, PSEN2, RASGRF1]

(0)

Neurophysiological process involving delta-type opioid receptor

[ADCY2, CREB1, HPCA, PRKAR1B, PRKAR2B]

(<0.01)

Neurophysiological process involving HTR1A receptor signaling

[ADCY2, ADCY5, HPCA, HTR1A, PRKAR1B, PRKAR2B]

(<0.01)

Neurophysiological process involving melatonin signaling

[ADCY2, ADCY5, CREB1, PRKAR1B, PRKAR2B, RORA]

(<0.01)

Neurophysiological process involving dopamine D2 receptor signaling

[ADCY2, ADCY5, CACNA1C, PRKAR1B, PRKAR2B]

(<0.01)

Neurophysiological process in circadian rhythm

[ADCAY1, CLOCK, CREB1, CACNA1C, RORA]

(<0.01)

Alpha-2 adrenergic receptor regulation of ion channels

[ADCY5, AKT3, CACNA1C, PRKAR1B, PRKAR2B]

(<0.01)

NGF signaling pathway in apoptosis and survival

[AKT3, CAD, GAB1]

(<0.01)

Transcription involving CREB pathway

(<0.01)

Role of activin A in cell differentiation and proliferation

[ADCY2, ADCY5, CREB1, NR5A1/SF1, PRKAR1B, PRKAR2B]

(<0.01)

GH-RH signaling

[ADCY2, ADCY5, CACNA1C, CREB1, PRKAR1B, PRKAR2B]

(<0.01)

ZNF202 in regulation of expression of genes involved in atherosclerosis

[ADRB3, APOL2, LPL]

(<0.01)

Regulation of lipid metabolism by niacin and isoprenaline

[ADCY2, ADCY5, ADRB3, PRKAR1B, PRKAR2B]

(<0.01)

Ligand-independent activation of ESR1 and ESR2

[ADCY2, ADCY5, AKT3, PRKAR1B, PRKAR2B]

(<0.01)

Relaxin signaling pathway

[ADCY5, AKT3, CREB1, PRKAR1B, PRKAR2B]

(<0.01)

Melanocyte development and pigmentation

[AKT3, CREB1, PRKAR1B, PRKAR2B, PRKG1]

(<0.01)

Down-regulated [18]

Immune response involving antigen presentation by MHC class I

[PDIA3]

(<0.01)

Vitamin B6 metabolism

[PHPT1]

(<0.02)

Blood coagulation and platelet degranulation

[F13A1]

(<0.03)

Cholesterol and sphingolipids intracellular transport

[PPIA]

(<0.03)

GSL metabolism

(<0.05)

Eutopic

Up-regulated [19]

Cell cycle at initiation of mitosis and regulation of G1/S transition

[LMNB2, PPP2R3A]

(<0.01)

Dopamine D2 receptor transactivation of PDGF receptor

[PPP2R3A]

(<0.01)

Apoptosis and survival involving caspase cascade, FAS signaling cascade and HTR1A signaling and anti-apoptosis by external signals via NF-kB

[LMNB2, PPP2R3A]

(<0.01)

G-protein signaling involving regulation CDC42 activity

[ARHGAP17]

(<0.01)

Gultamate regulation of Dopamine D1A receptor signaling

[PPP2R3A]

(<0.01)

PKA signaling

[PPP2R3A]

(<0.02)

Down-regulated [56]

Translation involving regulation of ElF2

[PPP1CC]

(0)

DNA damage involving NHEJ mechanisms of DSBs repair

[CSNK2A2]

(<0.02)

Cytoskeleton remodeling involving activin A

[FNTA]

(<0.02)

Olfactory transduction

[OR2H1]

(<0.02)

Cell cycle involving chromosome condensation in prometaphase, sister chromatic cohesion, regulation of S phase and initiation of mitosis

[HIST1H1C]

(<0.03)

Cadherin mediated cell adhesion

[PTPRF]

(<0.03)

GABA-A receptor mediated neurophysiological process

[PPP1C]

(<0.03)

MAG-dependent inhibition of neurite outgrowth

[MAG]

(<0.05)

Cell adhesion via PLAU signaling

[CSNK2A2]

(<0.05)

Ectopic

Up-regulated [0]

Down-regulated [91]

G-protein signaling involving Rap2A regulation pathway and G-protein alpha-s signaling cascade

[PRKAR2B, RAPGEF3]

(0)

Glycolysis and gluconeogenesis

[ENO2]

(0)

cAMP-Ca+2-dependent signal transduction

[PRKAR2B, RAPGEF3]

(<0.01)

G protein mediated regulation of MAPK-ERK signaling

[PRKAR2B, RAPGEF3]

(<0.01)

Development involving MAG, PACAP signaling, activin A, A2A and A2B receptor signaling and Hedgehog signaling

[MYH14, NANOG, NTF3, PRKAR2B, RAPGEF3]

(<0.01)

Regulation of eNOS activity

[PRKAR2B]

(<0.01)

CCR3 signaling in eosinophils

[FGR, MYH14]

(<0.02)

NMDA dependent neurophysiological process

[PRKAR2B, RAPGEF3]

(<0.03)

(<0.03)

CFTR expression, maturation and activity

[HSPA6, PRKAR2B]

(<0.03)